Clinical trials: DENGUE
Dengue
Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam
The study aims to retrospectively describe the demographic characteristics, comorbidity profiles, vaccination history and vaccination patterns of all individuals who have received at least one dose of TAK-003 (Qdenga) dengue…
- Trial name
- TAK-003 (NCT07501793)
- Where
- Vietnam
- Volunteers
- 800,000 people, healthy volunteers welcome
- Sponsor
- Tam Anh Research Institute
Dengue
TDENV PIV and LAV Dengue Prime-boost Strategy
The potential synergistic effect of administering 2 dengue vaccine candidates that were previously shown to be safe and immunogenic in humans will be evaluated in this study.
- Trial name
- NCT02239614
- Testing
- TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue (Virus); Fever, Sandfly, Sickle Cell Disease
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as dengue hemorrhagic fever or…
- Trial name
- DREPADENGUE (NCT07000747)
- Where
- Guadeloupe
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Virus
Genetic Determinants of the Antiviral Immune Response in Oceanian Populations
Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War.
- Trial name
- GEDIPOP (NCT06432855)
- Testing
- Blood collection, saliva collection
- Where
- New Caledonia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue
A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children
One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered approx. 1 year following the second dose
- Trial name
- NCT01843621
- Testing
- DEN vaccine F17
- Where
- Thailand
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue, Dengue Fever
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
- Trial name
- NCT01488890
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Yellow Fever
- Where
- 7 sites in United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Dengue viruses can cause dengue illness ranging from a mild illness to life-threatening disease. The purpose of this study is to evaluate the protective effectiveness of a dengue virus vaccine in healthy adults.
- Trial name
- NCT02021968
- Testing
- TetraVax-DV-TV003, rDEN2∆30-7169
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Dengue, Chikungunya Virus Infection
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Study setting: Medellin and Bello municipalities, Colombia Health condition(s) studied: Dengue, Zika and chikungunya virus infection Intervention: Deployment of Wolbachia-infected Aedes aegypti mosquitoes in Medellin and Bello.
- Conditions
- Dengue, Chikungunya Virus Infection, Zika Virus Infection
- Trial name
- WMP-COL (NCT03631719)
- Testing
- Wolbachia-carrying Ae.aegypti mosquitoes
- Where
- Colombia
- Volunteers
- 834 people
- Sponsor
- Universidad de Antioquia
Dengue
Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge
The purpose of this study is to evaluate the ability of a single dose of a live attenuated recombinant tetravalent dengue vaccine (TetraVax-DV-TV003, referred to as TV003) to protect against infection with a controlled human…
- Trial name
- NCT03416036
- Testing
- TetraVax-DV-TV003 (TV003), rDEN2Δ30-7169 (DENV-2), rDEN3Δ30 (DENV-3)
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Chikungunya
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the…
- Trial name
- NCT06973772
- Testing
- DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555)
- Where
- 7 sites in Brazil
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue
Impact of IIT-SIT on Dengue Clusters
This randomized controlled trial aims to evaluate the efficacy of Wolbachia-infected male mosquitoes combined with sterile insect technique (IIT-SIT) to mitigate active dengue transmission in Singapore.
- Trial name
- NCT06894901
- Testing
- Biological (Male Wolbachia-infected Aedes aegypti)
- Where
- Singapore
- Volunteers
- 900 people
- Sponsor
- National Environment Agency, Singapore
Dengue
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.
- Trial name
- NCT00350337
- Testing
- Pre-transfection F17, Post-transfection F17, Post-transfection F19
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Healthy Volunteers
A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months.
- Trial name
- NCT06060067
- Testing
- TDV
- Where
- 10 sites in India
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Takeda
Malaria, Dengue
Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR
Rural communities involved in agriculture are often at highest risk of insect-borne diseases in Southeast (SE) Asia. Skin-applied insect repellents may prove a useful means of reducing mosquito-borne diseases for those people…
- Conditions
- Malaria, Dengue, Japanese Encephalitis
- Trial name
- NCT00938379
- Testing
- 20% deet insect repellent
- Where
- Laos
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Dengue Fever, Papaya Leaf Extract
To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia
The goal of this clinical trial is to evaluate whether Carica papaya leaf extract (CPLE) can improve platelet counts in children aged 2 to 12 years diagnosed with dengue fever and thrombocytopenia.
- Conditions
- Dengue Fever, Papaya Leaf Extract, Pediatric Patients
- Trial name
- papaya leaf (NCT07172100)
- Testing
- Carica Papaya Leaf Extract Group, standard treatment
- Where
- Pakistan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ziauddin Hospital
Blood Donors, Dengue
Dengue Seroprevalence Study in Blood Donors in the French West Indies
Dengue is an infectious disease most prevalent in the world. This disease is endemic in the Caribbean, with an increase in seasonal rains.
- Trial name
- DengSeroprevAn (NCT01104740)
- Testing
- Biological sample collection
- Where
- 2 sites in Guadeloupe, Martinique
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Etablissement Français du Sang, Martinique
Dengue, Transaminitis
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
The purpose of this study is to determine whether regular dosage of paracetamol causes transaminitis (hepatitis) and evaluate its potency in the treatment of dengue infection.
- Trial name
- NCT02833584
- Testing
- Paracetamol
- Where
- 3 sites in Thailand
- Volunteers
- 123 people
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
- Trial name
- DPIV-001 (NCT01666652)
- Testing
- 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever, Pleural Effusion
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Rationale and Aims: Infection by dengue virus (DENV) causes major morbidity and mortality throughout the world. In 2012, an estimated 3.6 billion people live in areas at risk for DENV infection, including Singapore.
- Trial name
- KETODEN (NCT02673840)
- Testing
- Ketotifen
- Where
- 2 sites in Singapore
- Volunteers
- 110 people
- Sponsor
- National University Hospital, Singapore